Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial

Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial

(2011) R. F. Spiera et al.   ANNALS OF THE RHEUMATIC DISEASES

The c-Abl tyrosine kinase controls protein kinase Cδ-induced Fli-1 phosphorylation in human dermal fibroblasts

(2011) Andreea M. Bujor et al.   ARTHRITIS AND RHEUMATISM

A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease

(2011) Dinesh Khanna et al.   ARTHRITIS AND RHEUMATISM

Imatinib in active diffuse cutaneous systemic sclerosis: Results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center

(2011) Janet Pope et al.   ARTHRITIS AND RHEUMATISM

Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC/MS-MS

(2011) Stéphane Bouchet et al.   CLINICA CHIMICA ACTA

Imatinib Mesylate Has The Potential to Exert Its Efficacy by Down-Regulating The Plasma Concentration of Platelet-Derived Growth Factor in Patients With Pulmonary Arterial Hypertension

(2010) Masaru Hatano et al.   International Heart Journal

Imatinib treatment of generalized localized scleroderma (morphea)

(2010) Pia Moinzadeh et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Tyrosine Kinase Inhibitors in the Treatment of Systemic Sclerosis: From Animal Models to Clinical Trials

(2010) Naoki Iwamoto et al.   Current Rheumatology Reports

Imatinib Treatment for Idiopathic Pulmonary Fibrosis

(2009) Craig E. Daniels et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Molecular framework for response to imatinib mesylate in systemic sclerosis

(2009) Lorinda Chung et al.   ARTHRITIS AND RHEUMATISM

Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis

(2009) Alfiya Akhmetshina et al.   ARTHRITIS AND RHEUMATISM

Is imatinib mesylate a promising drug in systemic sclerosis?

(2008) P. L. A. van Daele et al.   ARTHRITIS AND RHEUMATISM

The Effect of Imatinib (Glivec®) on Scleroderma and Normal Dermal Fibroblasts: A Preclinical Study

(2008) A. Soria et al.   DERMATOLOGY

Imatinib for the treatment of refractory, diffuse systemic sclerosis

(2008) P. P. Sfikakis et al.   RHEUMATOLOGY